WHOOP Unveils First-Ever Wearable-Based Research on GLP-1 Therapies Beyond Weight Loss

Boston, MA — June, 2025 — The human performance company, WHOOP, has released a first-of-its-kind study to examine the effects of GLP-1 therapies beyond weight loss using wearable technology. The study, published in the American Journal of Physiology – Heart and Circulatory Physiology, explores how GLP-1 medications influence not only weight but also heart health and physical activity over a 12-week period. 

The rise in GLP-1 therapies is driven by growing evidence of their effectiveness not only in managing type 2 diabetes but also in promoting significant weight loss, fueling widespread demand for metabolic health solutions.

Understanding the Broader Effects of GLP-1 Therapies

WHOOP performance science researchers analyzed data from 132 WHOOP members—66 using GLP-1 medications and 66 matched controls—between November 7, 2023, and April 16, 2024. Using WHOOP and advanced causal inference methods, the study delivers key insights into how the body responds to GLP-1 therapies in real-world conditions.

Key Findings

• Significant Weight Loss: 90% of GLP-1 users achieved at least 5% weight loss in just 12 weeks, with an average reduction of 10% body weight—surpassing outcomes typically reported in pharmaceutical trials.
• Increased Physical Activity: On average, GLP-1 users added 30 more minutes of physical activity per week. Notably, those who exercised more experienced fewer heart-related side effects.
• Cardiovascular Health: Participants who remained physically active saw a smaller increase in resting heart rate (RHR), suggesting that regular exercise may help counteract cardiovascular side effects associated with GLP-1 medications.

Why It Matters

This study offers the first real-world evidence that physical activity may help mitigate cardiovascular side effects of GLP-1 therapy. It also reinforces the growing role of digital health and wearable technology in supporting weight loss, monitoring physiological responses, and promoting lasting lifestyle change.

Wearables like WHOOP empower individuals to build healthier habits by providing continuous insight into key metrics such as weight, heart rate, and activity levels. By helping members hit personalized strain targets, WHOOP supports cardiovascular health and enables GLP-1 users to track the broader physiological effects of their therapy.

While GLP-1 medications can be life-changing, combining them with regular exercise and a healthy diet is the most effective way to improve overall health and achieve sustainable results.

Interview time with the researchers is available upon request. 

About WHOOP

WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP 5.0 and WHOOP MG offer groundbreaking health innovations, including cardiovascular health features; Healthspan which quantifies Pace of Aging and provides members with their WHOOP Age; and first-of-its-kind wearable Blood Pressure Insights. WHOOP is the perfect health companion for anyone looking to optimize their health and performance. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. WHOOP is available to ship in 56 markets worldwide and the WHOOP app is available in English, French, German, Italian and Spanish (Latin America). WHOOP can be purchased on Amazon across the U.S., U.K., and Australia, as well as Best Buy (U.S.) Dick’s Sporting Goods (U.S.), Flipkart (India) and Virgin Megastore (GCC), and more.  

To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube. 

Contacts

press@whoop.com